300122 智飞生物
交易中 12-23 13:51:42
资讯
新帖
简况
智飞生物(300122.SZ)拟10股派2元 于12月25日除权除息
智通财经 · 12-17
智飞生物(300122.SZ)拟10股派2元 于12月25日除权除息
智飞生物:科技创新和技术突破是生物医药企业发展的源动力,也是公司实现高质量发展的必经之路
证券之星 · 12-06
智飞生物:科技创新和技术突破是生物医药企业发展的源动力,也是公司实现高质量发展的必经之路
《股市简讯》中国智飞生物早盘涨1.9%,与GSK优化并调整战略合作
路透中文 · 12-06
《股市简讯》中国智飞生物早盘涨1.9%,与GSK优化并调整战略合作
智飞生物(300122.SZ)与葛兰素史克延长带状疱疹疫苗独家经销协议 探索RSV疫苗商业化合作
智通财经 · 12-05
智飞生物(300122.SZ)与葛兰素史克延长带状疱疹疫苗独家经销协议 探索RSV疫苗商业化合作
智飞生物最新公告:与GSK签署了《独家经销和联合推广协议补充协议》
证券之星 · 12-05
智飞生物最新公告:与GSK签署了《独家经销和联合推广协议补充协议》
葛兰素史克:与智飞生物延长带状疱疹疫苗独家经销协议,探讨RSV疫苗潜在合作
美港电讯 · 12-05
葛兰素史克:与智飞生物延长带状疱疹疫苗独家经销协议,探讨RSV疫苗潜在合作
智飞生物(300122)11月20日股东户数13.36万户,较上期增加0.34%
证券之星 · 12-02
智飞生物(300122)11月20日股东户数13.36万户,较上期增加0.34%
智飞生物最新公告:重组结核杆菌融合蛋白(EC)继续纳入国家医保目录
证券之星 · 11-28
智飞生物最新公告:重组结核杆菌融合蛋白(EC)继续纳入国家医保目录
智飞生物(300122.SZ):重组结核杆菌融合蛋白(EC)继续纳入国家医保目录
智通财经 · 11-28
智飞生物(300122.SZ):重组结核杆菌融合蛋白(EC)继续纳入国家医保目录
智飞生物:未来三到五年自主研发产品将显著增加,竞争力提升
金融界 · 11-25
智飞生物:未来三到五年自主研发产品将显著增加,竞争力提升
智飞生物(300122)11月8日股东户数13.32万户,较上期增加5.91%
证券之星 · 11-25
智飞生物(300122)11月8日股东户数13.32万户,较上期增加5.91%
11月14日智飞生物跌5.07%,招商国证生物医药指数(LOF)C基金重仓该股
证券之星 · 11-14
11月14日智飞生物跌5.07%,招商国证生物医药指数(LOF)C基金重仓该股
3年市值跌没3000亿,智飞生物“重庆富豪父子”能否力挽狂澜?
市场资讯 · 11-03
3年市值跌没3000亿,智飞生物“重庆富豪父子”能否力挽狂澜?
智飞生物三季度多项“第一”:营收首降、存货新高、债务规模最大,为何坦承市场推广工作不足?
华夏时报 · 11-02
智飞生物三季度多项“第一”:营收首降、存货新高、债务规模最大,为何坦承市场推广工作不足?
智飞生物:10月30日接受机构调研,中信建投、国盛证券等多家机构参与
证券之星 · 10-31
智飞生物:10月30日接受机构调研,中信建投、国盛证券等多家机构参与
“疫苗一哥”智飞生物难逃“业绩劫”
市场资讯 · 10-28
“疫苗一哥”智飞生物难逃“业绩劫”
智飞生物(300122)2024年三季报简析:净利润减67.07%,应收账款上升
证券之星 · 10-27
智飞生物(300122)2024年三季报简析:净利润减67.07%,应收账款上升
智飞生物(300122)10月10日股东户数11.82万户,较上期增加0.17%
证券之星 · 10-26
智飞生物(300122)10月10日股东户数11.82万户,较上期增加0.17%
图解智飞生物三季报:第三季度单季净利润同比减103.69%
证券之星 · 10-26
图解智飞生物三季报:第三季度单季净利润同比减103.69%
智飞生物(300122.SZ):流感病毒裂解疫苗申请生产注册获受理
智通财经 · 10-25
智飞生物(300122.SZ):流感病毒裂解疫苗申请生产注册获受理
公司概况
公司名称:
重庆智飞生物制品股份有限公司
所属行业:
医药制造业
上市日期:
2010-09-28
主营业务:
重庆智飞生物制品股份有限公司是一家从事疫苗、生物制品的研发、生产和销售的公司;公司的主要产品包括预防流脑、宫颈癌、肺炎、轮状病毒等传染病的疫苗产品,也涵盖提供结核感染诊断、预防、治疗有效解决方案的药品。公司自成立以来,一贯注重研发与技术创新,通过十余年稳步增长的研发投入和持续深入的研发活动,形成了行业较领先的研发技术能力,并为公司可持续发展提供了技术根基。先后参与了科技部“863计划”,“现代医学技术”项目,科技部重大新药创制,国家新药创制重大专项等20余项国家级,省部级项目。
发行价格:
37.98
{"stockData":{"symbol":"300122","market":"SZ","secType":"STK","nameCN":"智飞生物","latestPrice":27.85,"timestamp":1734933102000,"preClose":28.16,"halted":0,"volume":12083301,"delay":0,"floatShares":1414000000,"shares":2394000000,"eps":1.5416,"marketStatus":"交易中","marketStatusCode":2,"change":-0.31,"latestTime":"12-23 13:51:42","open":28.21,"high":28.33,"low":27.68,"amount":338000000,"amplitude":0.0231,"askPrice":27.85,"askSize":82,"bidPrice":27.84,"bidSize":3,"shortable":0,"etf":0,"ttmEps":1.5416,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1734937200000},"adr":0,"adjPreClose":28.16,"symbolType":"stock","openAndCloseTimeList":[[1734917400000,1734924600000],[1734930000000,1734937200000]],"highLimit":30.98,"lowLimit":25.34,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":2393789747,"pbRate":2.14,"roa":"--","roe":"6.78%","epsLYR":3.3624,"committee":-0.539634,"marketValue":66667000000,"floatMarketCap":39388000000,"peRate":18.065646,"changeRate":-0.011,"turnoverRate":0.0085,"status":1},"requestUrl":"/m/hq/s/300122/wiki","defaultTab":"wiki","newsList":[{"id":"2492956767","title":"智飞生物(300122.SZ)拟10股派2元 于12月25日除权除息","url":"https://stock-news.laohu8.com/highlight/detail?id=2492956767","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492956767?lang=zh_cn&edition=full","pubTime":"2024-12-17 20:20","pubTimestamp":1734438050,"startTime":"0","endTime":"0","summary":"智通财经APP讯,智飞生物(300122.SZ)公告,公司2024年中期权益分派拟:向全体股东每10股派2元。除权除息日为:2024年12月25日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226184.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK0188","LU2580892789.USD","LU2580892862.HKD","BK0239","LU1328615791.USD","LU2148510915.USD","BK0046","LU1064130708.USD","BK0077","300122","LU1064131003.USD"],"gpt_icon":0},{"id":"2489404059","title":"智飞生物:科技创新和技术突破是生物医药企业发展的源动力,也是公司实现高质量发展的必经之路","url":"https://stock-news.laohu8.com/highlight/detail?id=2489404059","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489404059?lang=zh_cn&edition=full","pubTime":"2024-12-06 18:00","pubTimestamp":1733479219,"startTime":"0","endTime":"0","summary":"公司专一、专注、专业地在生物制药领域深耕细作,以科技创新为发展引擎,大力培育和发展新质生产力。智飞生物董秘:您好,截至2024年11月29日,公司普通股股东人数为131,041。公司2024年度经营业绩及财务数据请持续关注公司的定期报告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120600033023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["399441","LU1064131003.USD","300122","LU1064130708.USD","LU1328615791.USD","BK0077","LU2148510915.USD","LU2580892862.HKD","BK0188","BK0196","BK0239","LU2580892789.USD","BK0046","161726"],"gpt_icon":0},{"id":"2489283464","title":"《股市简讯》中国智飞生物早盘涨1.9%,与GSK优化并调整战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2489283464","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489283464?lang=zh_cn&edition=full","pubTime":"2024-12-06 10:04","pubTimestamp":1733450663,"startTime":"0","endTime":"0","summary":"《股市简讯》中国智飞生物早盘涨1.9%,与GSK优化并调整战略合作* 中国疫苗生产商--智飞生物300122.SZ周五早盘涨1.9%。* 公司与GSKGSK.L签署独家经销和联合推广协议补充协议,双方将根据市场变化、产品需求,采购与供应重组带状疱疹疫苗。2024-2029年合同期间,重组带状疱疹疫苗的预测采购金额约216亿元;双方将在中国大陆地区独家探索并积极促成初步为期10年的呼吸道合胞病毒疫苗商业化合作* 年初迄今,该股仍下跌超五成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241206:nL3S3N703R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","LU2148510915.USD","LU1064130708.USD","300122","BK0077","BK0046","LU1064131003.USD","LU1328615791.USD","LU2580892862.HKD","BK0239","LU2580892789.USD","BK0188"],"gpt_icon":0},{"id":"2489439624","title":"智飞生物(300122.SZ)与葛兰素史克延长带状疱疹疫苗独家经销协议 探索RSV疫苗商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2489439624","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489439624?lang=zh_cn&edition=full","pubTime":"2024-12-05 18:46","pubTimestamp":1733395597,"startTime":"0","endTime":"0","summary":"其中,公司与GSK调整了重组带状疱疹疫苗的采购计划。原《独家经销和联合推广协议》中双方约定的最低采购金额不再适用。公司将根据市场预期需求,向GSK分阶段采购协议产品,2024至2029年合同期间,重组带状疱疹疫苗的预测采购金额约216亿元,具体采购情况将根据合同约定和市场预期需求调整。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1220967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GSK.UK","159646","LU2148510915.USD","BK4532","BK0077","BK0188","LU1064130708.USD","BK4588","LU1829250122.USD","300122","BK0196","BK0046","LU1064131003.USD","GSK","LU2580892862.HKD","BK4585","BK0239","LU1328615791.USD","LU2580892789.USD","BK4007"],"gpt_icon":0},{"id":"2489139435","title":"智飞生物最新公告:与GSK签署了《独家经销和联合推广协议补充协议》","url":"https://stock-news.laohu8.com/highlight/detail?id=2489139435","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489139435?lang=zh_cn&edition=full","pubTime":"2024-12-05 18:10","pubTimestamp":1733393410,"startTime":"0","endTime":"0","summary":"智飞生物公告,公司与葛兰素史克生物、葛兰素史克香港(以下合称:“GSK”)签署了《独家经销和联合推广协议补充协议》,优化调整了2023年10月8日签署的原《独家经销和联合推广协议》中约定的重组带状疱疹疫苗采购计划的相关条款,并进一步拓展了公司在中国大陆地区拥有独家进口、分销和共同推广重组带状疱疹疫苗的权利期限。此外,补充协议还进一步明确公司将与GSK独家探索并积极促成在中国大陆地区初步为期10年的呼吸道合胞病毒(RSV)疫苗商业化合作。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120500031483.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122","LU1064130708.USD","LU1328615791.USD","BK0077","LU1064131003.USD","LU2580892789.USD","BK0046","BK0188","BK0196","LU2580892862.HKD","LU2148510915.USD","BK0239"],"gpt_icon":0},{"id":"2489484848","title":"葛兰素史克:与智飞生物延长带状疱疹疫苗独家经销协议,探讨RSV疫苗潜在合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2489484848","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489484848?lang=zh_cn&edition=full","pubTime":"2024-12-05 16:37","pubTimestamp":1733387873,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["159646","LU1400636491.USD","BK4585","LU0321505868.SGD","LU1202635105.USD","LU0971552830.HKD","LU0225284248.USD","LU0211331839.USD","IE00BQJZX424.USD","LU1064131003.USD","LU2580892789.USD","LU1015430645.USD","LU1829250122.USD","BK0239","BK0077","BK0188","LU0289739699.SGD","LU0971552673.USD","LU1064927863.SGD","BK5011","BK4007","IE0034235071.USD","LU1064130708.USD","LU1302929846.USD","LU1228905540.USD","LU1328615791.USD","LU1670756490.USD","LU0545562505.USD","LU1487256676.USD","LU1481599808.USD","LU0203347892.USD","LU1098665638.USD","300122","GSK.UK","LU1400636657.SGD","BK0046","LU1400636574.HKD","LU0058720904.USD","LU1481600234.SGD","LU0985481810.HKD","GSK","LU1035777561.USD","LU0109981661.USD","LU1645745479.HKD","LU0225771236.USD","LU0203345920.USD","LU2580892862.HKD","LU1046248800.SGD","IE00BWDBJ516.SGD","LU0321505439.SGD"],"gpt_icon":0},{"id":"2488262866","title":"智飞生物(300122)11月20日股东户数13.36万户,较上期增加0.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2488262866","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488262866?lang=zh_cn&edition=full","pubTime":"2024-12-02 17:06","pubTimestamp":1733130371,"startTime":"0","endTime":"0","summary":"证券之星消息,近日智飞生物披露,截至2024年11月20日公司股东户数为13.36万户,较11月8日增加453.0户,增幅为0.34%。在生物制品行业个股中,智飞生物股东户数高于行业平均水平,截至11月20日,生物制品行业平均股东户数为3.39万户。根据统计,智飞生物2024年11月8日至2024年11月20日,主力资金净流出8.26亿元,游资资金净流入2.7亿元,散户资金净流入5.56亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120200021765.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK0188","BK0077","300122","LU1328615791.USD","LU1064130708.USD","LU2580892862.HKD","BK0196","BK0239","LU2148510915.USD","LU2580892789.USD","BK0046"],"gpt_icon":0},{"id":"2486971703","title":"智飞生物最新公告:重组结核杆菌融合蛋白(EC)继续纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2486971703","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486971703?lang=zh_cn&edition=full","pubTime":"2024-11-28 19:39","pubTimestamp":1732793989,"startTime":"0","endTime":"0","summary":"智飞生物公告,公司全资子公司安徽智飞龙科马生物制药有限公司的重点产品重组结核杆菌融合蛋白(EC)(商品名:宜卡)纳入《2024年国家医保目录》。重组结核杆菌融合蛋白(EC)适用于结核杆菌感染诊断。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112800032868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","LU2148510915.USD","LU1064130708.USD","300122","BK0077","BK0046","LU1064131003.USD","LU1328615791.USD","LU2580892862.HKD","BK0239","LU2580892789.USD","BK0188"],"gpt_icon":0},{"id":"2486360398","title":"智飞生物(300122.SZ):重组结核杆菌融合蛋白(EC)继续纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2486360398","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486360398?lang=zh_cn&edition=full","pubTime":"2024-11-28 17:04","pubTimestamp":1732784696,"startTime":"0","endTime":"0","summary":"智通财经APP讯,智飞生物(300122.SZ)公告,公司全资子公司安徽智飞龙科马生物制药有限公司的重点产品重组结核杆菌融合蛋白(EC)(商品名:宜卡)纳入《2024年国家医保目录》。公告显示,重组结核杆菌融合蛋白(EC)(商品名:宜卡)适用于结核杆菌感染诊断,推荐用于6月龄及以上婴儿、儿童及65周岁以下成人。本品皮试结果不受卡介苗(BCG)接种的影响,可用于辅助结核病的临床诊断。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1217254.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300122","LU2580892789.USD","BK4201","LU1064130708.USD","LU1328615791.USD","BK0196","BK0239","BK0077","BK0188","LU2580892862.HKD","BK0046","LU2148510915.USD","EC","LU1064131003.USD"],"gpt_icon":0},{"id":"2486845085","title":"智飞生物:未来三到五年自主研发产品将显著增加,竞争力提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2486845085","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486845085?lang=zh_cn&edition=full","pubTime":"2024-11-25 20:22","pubTimestamp":1732537373,"startTime":"0","endTime":"0","summary":"作为国内疫苗行业的佼佼者,智飞生物一直密切关注HPV疫苗市场的动态。智飞生物作为行业内的领军企业,积极响应国家政策,不断加大HPV疫苗的推广力度,为提高民众健康水平做出了积极贡献。智飞生物预计,未来三到五年内,自主研发产品数量将显著增加,自主产品在营业收入中的占比也将大幅提升。展望未来,智飞生物将继续坚持研发创新和市场拓展并重的战略方针,不断提升自身的创新能力和市场竞争力。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/25202245657803.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU1064130708.USD","BK0239","LU2580892789.USD","BK0077","LU2148510915.USD","LU1064131003.USD","LU2580892862.HKD","LU1328615791.USD","BK0046","BK0188","300122","BK0196"],"gpt_icon":0},{"id":"2486708841","title":"智飞生物(300122)11月8日股东户数13.32万户,较上期增加5.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486708841","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486708841?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:05","pubTimestamp":1732525551,"startTime":"0","endTime":"0","summary":"证券之星消息,近日智飞生物披露,截至2024年11月8日公司股东户数为13.31万户,较10月18日增加7435.0户,增幅为5.91%。户均持股数量由上期的1.9万股减少至1.8万股,户均持股市值为54.96万元。在生物制品行业个股中,智飞生物股东户数高于行业平均水平,截至11月8日,生物制品行业平均股东户数为3.39万户。根据统计,智飞生物2024年10月18日至2024年11月8日,主力资金净流出12.74亿元,游资资金净流入4.34亿元,散户资金净流入8.4亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112500021800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","300122","LU1064130708.USD","LU1328615791.USD","BK0077","LU2148510915.USD","LU2580892862.HKD","BK0188","BK0196","BK0239","BK0046","LU2580892789.USD"],"gpt_icon":0},{"id":"2483423528","title":"11月14日智飞生物跌5.07%,招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483423528","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483423528?lang=zh_cn&edition=full","pubTime":"2024-11-14 16:17","pubTimestamp":1731572260,"startTime":"0","endTime":"0","summary":"证券之星消息,11月14日智飞生物跌5.07%,收盘报30.88元,换手率3.02%,成交量42.76万手,成交额13.51亿元。根据2024基金Q3季报公募基金重仓股数据,重仓该股的公募基金共79家,其中持有数量最多的公募基金为招商国证生物医药指数C。招商国证生物医药指数C目前规模为21.69亿元,最新净值0.425,较上一交易日下跌1.21%,近一年下跌18.06%。招商国证生物医药指数C的前十大重仓股如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111400025974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122","BK0046","LU1064130708.USD","LU2148510915.USD","BK0188","LU2580892862.HKD","LU1064131003.USD","BK0196","BK0077","BK0239","399441","161726","LU1328615791.USD","LU2580892789.USD"],"gpt_icon":0},{"id":"2480338290","title":"3年市值跌没3000亿,智飞生物“重庆富豪父子”能否力挽狂澜?","url":"https://stock-news.laohu8.com/highlight/detail?id=2480338290","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480338290?lang=zh_cn&edition=full","pubTime":"2024-11-03 11:42","pubTimestamp":1730605320,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 10月26日,智飞生物三季报显示,营收同比下降41.98%,而在连续4个季度同比下滑后,第三季度净亏损8369.64万元。2021年4月,智飞生物市值近3700亿元,创始人蒋仁生借此坐上“重庆首富”的宝座。 智飞生物素有疫苗“金牌代理”之称,代理产品中,默沙东授权的九价HPV疫苗为其贡献了绝大部分业绩。 智飞生物该如何化解亏损?","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2024-11-03/doc-incuuazm3476661.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300122","LU2580892789.USD","LU1064130708.USD","LU1328615791.USD","BK0196","BK0239","BK0077","BK0188","BK0046","LU2148510915.USD","LU2580892862.HKD","LU1064131003.USD"],"gpt_icon":0},{"id":"2480963468","title":"智飞生物三季度多项“第一”:营收首降、存货新高、债务规模最大,为何坦承市场推广工作不足?","url":"https://stock-news.laohu8.com/highlight/detail?id=2480963468","media":"华夏时报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480963468?lang=zh_cn&edition=full","pubTime":"2024-11-02 09:28","pubTimestamp":1730510880,"startTime":"0","endTime":"0","summary":"与以往不同的是,此番智飞生物拿下了多项“第一”,例如营收首次下滑、存货创历史新高、短期债务规模最大等等。先看智飞生物在市场推广方面做了哪些工作。可以看出,智飞生物在市场推广上的投入逐年增加,反映了其对市场推广工作的高度重视。而今年前三季度,智飞生物经营性现金流大幅流出30.65亿元,实属罕见。大规模举债下,智飞生物前三季度的利息费用已经超过了去年全年。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-11-02/doc-incurtuh2360297.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-11-02/doc-incurtuh2360297.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300122"],"gpt_icon":0},{"id":"2479316710","title":"智飞生物:10月30日接受机构调研,中信建投、国盛证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2479316710","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479316710?lang=zh_cn&edition=full","pubTime":"2024-10-31 11:07","pubTimestamp":1730344027,"startTime":"0","endTime":"0","summary":"证券之星消息,2024年10月30日智飞生物发布公告称公司于2024年10月30日接受机构调研,中信建投、国盛证券、睿远基金、申万菱信参与。适龄女性接种 HPV 疫苗具有必要性。根据世界卫生组织发布的《2024 年全球结核病报告》,2023年全球因结核病死亡人数为 125 万,结核病重返全球单一传染病死因首位。公司积极响应世界卫生组织提出的终止结核病战略,积极推动公司结核病诊疗产品在结核病高负担国家的注册上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100019222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","LU1064130708.USD","BK0276","LU2580892862.HKD","LU1328615791.USD","BK0188","LU2148510915.USD","LU1064131003.USD","LU2580892789.USD","300122","BK0196","161027","BK0239","601066","BK0046"],"gpt_icon":0},{"id":"2478810073","title":"“疫苗一哥”智飞生物难逃“业绩劫”","url":"https://stock-news.laohu8.com/highlight/detail?id=2478810073","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478810073?lang=zh_cn&edition=full","pubTime":"2024-10-28 20:40","pubTimestamp":1730119200,"startTime":"0","endTime":"0","summary":" 浓眉大眼的疫苗一哥智飞生物,也难逃三季度的业绩雷。财报显示,智飞生物单季度归母净利润8年来首次出现亏损,亏损的原因则是HPV疫苗收入未达预期。而随着HPV疫苗竞争的白热化,智飞生物的代理生意红利将逐渐消退。 此次业绩“暴雷”,打破了智飞生物靠代理生意“躺平”的幻想,摆在公司面前的,除了业绩下滑,还有存货翻倍、短期借款大幅增加、经营现金流转负的经营压力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2024-10-28/doc-incucmqv8551025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0077","LU1064130708.USD","LU2580892862.HKD","LU1328615791.USD","BK0188","LU2148510915.USD","LU1064131003.USD","LU2580892789.USD","300122","BK0196","159646","BK0239","BK0046"],"gpt_icon":0},{"id":"2478718482","title":"智飞生物(300122)2024年三季报简析:净利润减67.07%,应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2478718482","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478718482?lang=zh_cn&edition=full","pubTime":"2024-10-27 10:58","pubTimestamp":1729997887,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期智飞生物发布2024年三季报。截至本报告期末,公司营业总收入227.86亿元,同比下降41.98%,归母净利润21.51亿元,同比下降67.07%。本报告期智飞生物应收账款上升,应收账款同比增幅达41.78%。去年的净利率为15.25%,算上全部成本后,公司产品或服务的附加值高。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102700011285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122"],"gpt_icon":0},{"id":"2478963942","title":"智飞生物(300122)10月10日股东户数11.82万户,较上期增加0.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478963942","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478963942?lang=zh_cn&edition=full","pubTime":"2024-10-26 17:03","pubTimestamp":1729933404,"startTime":"0","endTime":"0","summary":"证券之星消息,近日智飞生物披露,截至2024年10月10日公司股东户数为11.82万户,较9月30日增加198.0户,增幅为0.17%。在生物制品行业个股中,智飞生物股东户数高于行业平均水平,截至10月10日,生物制品行业平均股东户数为3.35万户。根据统计,智飞生物2024年9月30日至2024年10月10日,主力资金净流出8.08亿元,游资资金净流入1.93亿元,散户资金净流入6.15亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102600008550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1328615791.USD","300122","LU1064130708.USD","BK0046","LU1064131003.USD","BK0077","LU2148510915.USD","BK0188","BK0239","LU2580892862.HKD","LU2580892789.USD","BK0196"],"gpt_icon":0},{"id":"2478614951","title":"图解智飞生物三季报:第三季度单季净利润同比减103.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478614951","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478614951?lang=zh_cn&edition=full","pubTime":"2024-10-26 00:51","pubTimestamp":1729875063,"startTime":"0","endTime":"0","summary":"证券之星消息,智飞生物2024年三季报显示,公司主营收入227.86亿元,同比下降41.98%;归母净利润21.51亿元,同比下降67.07%;扣非净利润21.43亿元,同比下降66.41%;其中2024年第三季度,公司单季度主营收入45.28亿元,同比下降69.46%;单季度归母净利润-8369.64万元,同比下降103.69%;单季度扣非净利润-8741.52万元,同比下降104.03%;负债率41.46%,财务费用5431.14万元,毛利率27.23%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102600000594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122"],"gpt_icon":0},{"id":"2478937274","title":"智飞生物(300122.SZ):流感病毒裂解疫苗申请生产注册获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2478937274","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478937274?lang=zh_cn&edition=full","pubTime":"2024-10-25 23:25","pubTimestamp":1729869908,"startTime":"0","endTime":"0","summary":"智通财经APP讯,智飞生物(300122.SZ)公告,公司近日收到全资子公司安徽智飞龙科马生物制药有限公司(简称“智飞龙科马”)报告,由智飞龙科马自主研发的流感病毒裂解疫苗申请生产注册获得国家药品监督管理局出具的《受理通知书》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1200536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","LU2148510915.USD","LU2580892789.USD","LU1064130708.USD","300122","BK0077","BK0046","LU1064131003.USD","LU1328615791.USD","LU2580892862.HKD","BK0239","159646","BK0188"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2010-09-28","address":"重庆市江北区庆云路1号50层","stockEarnings":[{"period":"1week","weight":-0.0222},{"period":"1month","weight":-0.0663},{"period":"3month","weight":0.3597},{"period":"6month","weight":0.0103},{"period":"1year","weight":-0.5007},{"period":"ytd","weight":-0.5252}],"companyName":"重庆智飞生物制品股份有限公司","boardCode":"AI0027","perCapita":"10792股","boardName":"医药制造业","registeredCapital":"239378万元","compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":0},{"period":"3month","weight":0.2307},{"period":"6month","weight":0.1234},{"period":"1year","weight":0.154},{"period":"ytd","weight":0.1321}],"survey":" 重庆智飞生物制品股份有限公司是一家从事疫苗、生物制品的研发、生产和销售的公司;公司的主要产品包括预防流脑、宫颈癌、肺炎、轮状病毒等传染病的疫苗产品,也涵盖提供结核感染诊断、预防、治疗有效解决方案的药品。公司自成立以来,一贯注重研发与技术创新,通过十余年稳步增长的研发投入和持续深入的研发活动,形成了行业较领先的研发技术能力,并为公司可持续发展提供了技术根基。先后参与了科技部“863计划”,“现代医学技术”项目,科技部重大新药创制,国家新药创制重大专项等20余项国家级,省部级项目。","serverTime":1734933104463,"listedPrice":37.98,"stockholders":"131041人(较上一季度减少1.92%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"智飞生物,300122,智飞生物股票,智飞生物股票老虎,智飞生物股票老虎国际,智飞生物行情,智飞生物股票行情,智飞生物股价,智飞生物股市,智飞生物股票价格,智飞生物股票交易,智飞生物股票购买,智飞生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}